非酒精性脂肪肝 | Non-Alcoholic Fatty Liver

SKU cs03
HK$4,663.00
Out of stock
1
Product Details

非酒精性脂肪肝

非酒精性脂肪肝(NAFLD)是一種日益被認可的疾病,在普通人群中的患病率上升了25%。鑒於疫情的新增,監管機构已經確定了未滿足的醫療需求,並實施了加快NASH治療藥物開發的舉措。

Obeti膽酸是唯一一種在第3階段中期結果中具有顯著益處的藥物,並且仍然是作為非酒精性脂肪性肝炎治療藥物首次獲得有條件準予的候選藥物。然而,在最近的試驗中,這些藥物的單一治療只有不到三分之一的非酒精性脂肪性肝炎患者的組織學緩解。因此,非酒精性脂肪性肝炎治療的未來必然是兩種不同藥物的聯合治療,具有互補作用。(1)

輕中度脂肪肝 - 多學科復康組合 (1個月試用份量)

顯著進程: 約2-3個月

多學科復康組合:

  • 藥物及其他醫療方案, 請遵醫從醫生建議
  • 飲食營養請依營養師指引
  • 運動及或心理輔導, 請參考各專家建議
  • 為免錯誤診斷及漏診, 請上傳最近一個月醫院的專業診斷報告

不適合使用:

  • 肝纖維化及硬化
  • 酒精性脂肪肝
  • 對該組合的成份有過敏
  • 胃潰瘍

或適合的補充劑輔助組合: (1個月試用份量)

  1. 醇脂膽酸 x 3瓶
  2. 螯合研究 x 3瓶
  3. 酶素研究 x 1瓶
  4. 高濃酸酯蜂膠液 x 3瓶

生活配合:

  • 不能吃太飽, 以8成飽肚為主
  • 碳水化合物食物儘量減少份量
  • 高脂、高膽固醇食物必須避開少吃
  • 多喝白開水, 每天2公升
  • 多吃膳食纖維食物
  • 戒掉夜宵習慣
  • 不適宜自行補充鈣及鐵等礦物質
  • 早睡早起, 不要熬夜
  • 每天不少於1萬步中速步行

飲食戒口:

  • 煎炸烤燒食物儘量少吃
  • 動物肝臟、血液等高鐵質食物不要吃

注意:

  • 為營養補充品,不能代替藥物。
  • 懷孕或哺乳期女士、嬰幼兒,請不要食用本品。
  • 如不瞭解問題原因或問題持續,請儘快諮詢醫生。

如你有任何疾病, 請遵照閣下醫生的完整醫療方案; 而是否使用多學科復康方案前, 你必須咨詢主診醫生的意見, 如果閣下的主診醫生不建議您加入補充劑調理組合, 請你不要使用。如果你需要尋求其他醫生作第二咨詢, 閣下可聯絡我們線上<無邊界醫生>或你自己城市內的其他專業醫生的再診斷。

__

Non-Alcoholic Fatty Liver
Non-alcoholic fatty liver disease (NAFLD) is an increasingly common condition, and its prevalence has increased by 25% in the general population especially since the Covid19 outbreak. Hence, acceleration of the development of NASH therapeutic drugs by regulators.
Obeticholic acid is the only drug with significant benefit in the phase 3 interim results and remains the candidate for first conditional approval as a NASH therapeutic. However, monotherapy with these drugs leads to a histological resolution of NASH in less than one-third of patients in recent trials. Therefore, the future of NASH therapy will putatively be a combination therapy of two different drug classes with complementary effects. (1)
Mild to moderate fatty liver multidisciplinary rehabilitation combo (1-month trial)
  • Significant progress: about 2-3 months.
Multidisciplinary rehabilitation program
  • Please follow doctor's advice on drugs and other medical plans.
  • Please follow dietitian's guidelines for diet and nutrition.
  • For sports and or psychological counseling, please refer to experts' suggestions.
  • To avoid misdiagnosis or incorrect diagnosis, please upload medical report/s by professional bodies dated within a month.
Not suitable for these conditions:
  • Hepatic fibrosis and sclerosis
  • Alcoholic fatty liver
  • Allergic to the ingredients of the combination
  • Gastric ulcer

Suggested combination of supplements: (1-month trial)

  1. CT Cholic Acid x 3 bottles
  2. Chelation Study x 3 bottles
  3. Scienzyme Study x 1 bottle
  4. High Concentration Matrine Propolis x 3 bottles
Lifestyle recommendations:
  • Don't eat too full; suggest 80% full
  • Try to reduce the intake of carbohydrate
  • Avoid or reduce high fat and cholesterol food
  • Drink plenty of boiled water, 2 liters a day
  • Eat more dietary fiber food
  • Get rid of night snack habit
  • Intake of minerals supplementation such as calcium and iron is not suitable
  • Go to bed early and get up early; don't stay up late
  • No less than 10000 steps of medium speed walking every day
Diet recommendations:
  • Try to eat less fried and roasted food
  • Do not eat high iron foods such as animal liver and blood
Caution:
  • Product/s is categorized as nutritional supplement and cannot replace drugs.
  • Not suitable for pregnant or lactating women, infants and young children.
  • If you do not know the cause of your health condition or the problem continues, please consult your doctor as soon as possible.
If you have a medical condition, please follow your doctor's medical treatment plan. Do consult your medical doctor before using the Multidisciplinary Rehabilitation Program (MRP). Please do not proceed if your medical doctor does not recommend the use of our MRP. If you'd like to seek a second opinion from other doctors, you may contact our online "Doctors Without Border", or other professional doctors at your convenience.

__


Ref / 參考文獻:
  1. An update on drug development for the treatment of nonalcoholic fatty liver disease – from ongoing clinical trials to future therapy. Monika Rau &Andreas Geier. https://doi.org/10.1080/17512433.2021.1884068

__


本品等並非根據《藥劑業及毒藥條例》或《中醫藥條例》注册。任何對其提出的宣稱均不受此類登記評估的約束。本產品不用於診斷、治療或預防任何疾病。

This product is not registered under the Pharmacy and Poisons Ordinance or the Chinese Medicine Ordinance. Any claim made for it has not been subject to evaluation for such registration. This product is not intended to diagnose, treat or prevent any disease.

Save this product for later